Although subtypes of pancreatic ductal adenocarcinoma (PDAC) have been described, this malignancy is clinically still treated as a single disease. Here we present patient-derived models representing the full spectrum of previously identified quasimesenchymal (QM-PDA), classical and exocrine-like PDAC subtypes, and identify two markers-HNF1A and KRT81-that enable stratification of tumors into different subtypes by using immunohistochemistry. Individuals with tumors of these subtypes showed substantial differences in overall survival, and their tumors differed in drug sensitivity, with the exocrine-like subtype being resistant to tyrosine kinase inhibitors and paclitaxel. Cytochrome P450 3A5 (CYP3A5) metabolizes these compounds in tumors of the exocrine-like subtype, and pharmacological or short hairpin RNA (shRNA)-mediated CYP3A5 inhibition sensitizes tumor cells to these drugs. Whereas hepatocyte nuclear factor 4, alpha (HNF4A) controls basal expression of CYP3A5, drug-induced CYP3A5 upregulation is mediated by the nuclear receptor NR1I2. CYP3A5 also contributes to acquired drug resistance in QM-PDA and classical PDAC, and it is highly expressed in several additional malignancies. These findings designate CYP3A5 as a predictor of therapy response and as a tumor cell-autonomous detoxification mechanism that must be overcome to prevent drug resistance. npg
PDAC is a very aggressive disease with poor prognosis 1 . In both Europe and the USA, pancreatic cancer is the fourth leading cause of cancer deaths 2, 3 . Treatment with gemcitabine 4 , the FOLFIRINOX scheme (a combination of oxaliplatin, irinotecan, fluorouracil and leucovorin) 5 or the nanoparticle albumin-bound paclitaxel (nab-paclitaxel) 6 offer only a modest increase in overall survival. Despite extensive testing of targeted therapies in clinical trials, all of the examined compounds confer little or no survival benefit in unselected cohorts of individuals with PDAC 1, 7, 8 .
Although patient stratification according to molecular characteristics has not yet been performed in clinical trials for PDAC, transcriptional profiling of whole-tumor tissues suggest the existence of subtypes of PDAC that differ in patient survival and tumor metastasis 9, 10 . Additionally, three PDAC subtypes (classical, QM-PDA and exocrine-like) 11 were described on the basis of gene expression profiling analyses of laser capture-microdissected epithelial tumors. However, in a larger panel of human and mouse PDAC cell lines, only the classical and the QM-PDA subtypes were identified 11 , suggesting that currently used PDAC cell lines inadequately represent the heterogeneity of human PDAC. In addition, the classical and QM-PDA subtypes were suggested to differ in their responses to a range of chemotherapeutics, and the drug sensitivity of the exocrine-like subtype has yet to be determined 11 .
Although resistance of PDAC to therapy is well described 1 , little is known about the molecular mechanisms mediating it. Members of the cytochrome P450 (CYP) enzyme family have been previously investigated only with regards to a role in systemic drug metabolism 12, 13 or their up-or downregulation in solid tumors as compared to normal tissues 14 . Thus, the functional role and impact of CYPs on tumor cell-autonomous drug resistance remains mostly unknown 14, 15 . classical subtype (PACO2 and PACO17), whereas three were enriched for the exocrine-like subtype (PACO10, PACO14 and PACO18) and three for the QM-PDA subtype (PACO7, PACO9 and PACO19). Taken together, these results demonstrate that our models faithfully preserve the histomorphological characteristics of the originating tumors and, for the first time, enable the study of functional differences between all three PDAC subtypes.
Prognostic value of HNF1A and KRT81 expression Because histopathology supplemented by immunohistochemistry is still currently the standard method for tumor subtyping, we sought to identify surrogate protein markers for each of these three PDAC subtypes to facilitate clinical patient stratification. We subjected PACO cell lines to array-based gene expression profiling. To generate a candidate biomarker list, we filtered a list of genes that were strongly (>5-fold; P < 0.05) differentially expressed between the different PACO subtypes for candidates that showed heterogeneous expression across PDAC specimens in the Protein Atlas database 19 . Additionally, GSEA of transcription factor activity gene sets on the original expression profiles revealed an enrichment of transcripts with binding sites for the transcription factor HNF1A in the exocrine-like subtype, suggesting HNF1A as a putative marker for this subtype (data not shown). We stained PACO lines and xenografts for all marker candidates, and npg evaluated signal intensity and subtype specificity ( Supplementary  Table 4 ). We excluded markers that stained only weakly or that were not subtype specific. This analysis identified positive nuclear staining for HNF1A specifically in exocrine-like PDAC cells, whereas staining for cytokeratin 81 (KRT81) was specific for cells of the QM-PDA PDAC subtype ( Fig. 1b) . Additionally, in The Cancer Genome Atlas (TCGA) pancreatic adenocarcinoma (PAAD) cohort, KRT81 expression also inversely correlated with that of HNF1A (Supplementary Fig. 1c ). None of the candidate markers for the classical PDAC subtype showed a reliable and exclusive staining pattern in cells of this subtype. Nevertheless, the specificity of KRT81 and HNF1A staining allowed us to define classical subtype specimens as being double negative (DN) for these markers. Hence, we defined surrogate markers for the three subtypes as KRT81 + HNF1A − for the QM-PDA subtype, KRT81 − HNF1A + for the exocrine-like subtype and KRT81 − HNF1A − for the classical subtype. We verified the association of our marker-defined subtypes with the PDAssigner signatures in an independent validation cohort of primary PDAC xenografts ( Supplementary Table 5 ). Principal component analysis (PCA) demonstrated that transcriptional profiles clustered according to KRT81-and HNF1A-defined subtypes ( Supplementary  Fig. 1d ). Hierarchical clustering using the PDAssigner genes further showed a separation into three groups, revealing a high concordance with our marker-defined groups (Supplementary Fig. 1e ). GSEA of the marker-defined groups revealed enrichment of the QM-PDA signature in the KRT81 + tumors and of the exocrine-like signature in the HNF1A + tumors. The DN tumors were enriched for all three signatures and could not be unequivocally assigned ( Supplementary  Fig. 1f ), suggesting that the PDAssigner signature would need to be improved for a more robust classification. Collectively, our surrogate markers separate the validation cohort into three distinct groups, of which the KRT81 + and HNF1A + cases are enriched in the respective PDAssigner-defined subtypes 11 . Next we tested whether subtype stratification of a cohort of 231 individuals with PDAC, by using these two markers is associated with clinical outcome. In a retrospective study using immunohistochemistry, we designated these PDAC tumors as 45% DN, 35% KRT81 + and 20% HNF1A + (Fig. 1c,d and Supplementary  Table 6 ). We also identified 14 KRT81 + HNF1A + double-positive specimens and excluded them from the analysis. Log-rank analysis revealed significant differences in overall survival of individuals with PDAC of different subtypes (P < 0.001) ( Fig. 1d) . Subjects with HNF1A + tumors had the best mean survival (43.5 months), followed by those with the DN subtype (26.3 months) and the KRT81 + subtype (16.5 months). Moreover, Cox proportional-hazards multivariate regression analysis revealed that the survival impact of the subtype classification is independent of established conventional prognostic factors such as stage, grade and age 20, 21 ( Supplementary Table 7 ). Subtype was associated with grade, as the HNF1A + cases were more differentiated (24% grade 3), the KRT81 + samples tended to be less differentiated (50.6% grade 3), and the DN cases ranged in between (41.5% grade 3) ( Supplementary Table 8 ). Although this association was significant (P = 0.01), grade alone was insufficient to predict subtype. Hence, HNF1A and KRT81 can be used to stratify patients into subtypes of PDAC that are associated with differences in overall patient survival.
Exocrine-like PDAC cells are resistant to tyrosine kinase inhibitors
To address whether the subtypes differ in drug sensitivity, PACO lines were treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib and the SRC and ABL1 tyrosine kinase-selective TKI dasatinib, which are approved or under investigation for the treatment of PDAC, respectively [22] [23] [24] .
We treated PACO lines of each subtype with 1 µM (Fig. 2a ) or 10 µM ( Supplementary Fig. 2a ) erlotinib and dasatinib, which corresponds to 0.3-to 3-fold and 6-to 60-fold peak plasma concentrations reported in humans, respectively 25, 26 . Analysis after 48 h of treatment revealed that the classical and QM-PDA cells were drug sensitive, whereas the exocrine-like cells were almost completely drug resistant. To exclude the possibility that the observed resistance was due to varying proliferation rates, we treated the PACO lines as described above for 7 d and confirmed the difference in drug response (Supplementary Fig. 2b,c) . To identify the mechanisms underlying the observed drug resistance, we used GSEA to compare the exocrine-like PACO lines and xenografts with the classical and the QM-PDA PACO lines and xenografts. This analysis revealed an enrichment of signatures comprising genes involved in xenobiotic biotransformation in the exocrine-like PDAC models ( Fig. 2b and Supplementary Fig. 2d,e ). For validation we analyzed an independent data set generated from laser-microdissected PDAC 11 and confirmed the upregulation of similar gene sets in exocrine-like PDAC samples ( Supplementary Fig. 2f ). Thus, xenobiotic biotransformation might contribute to the observed drug resistance in cells of the exocrine-like PDAC subtype.
CYP family enzymes systemically metabolize small-molecule drugs by oxidation, resulting in potential inactivation of the drugs 27, 28 . To test whether xenobiotic biotransformation is indeed involved in the observed drug resistance, we pretreated cells of each subtype with the pan-CYP inhibitor ketoconazole 14 . We pretreated one PACO line of each subtype with 100 nM ketoconazole or vehicle for 2 h, added serial dilutions of erlotinib or dasatinib and determined relative cell viability after 48 h. To compare TKI effects across independent experiments, we calculated activity areas as previously described 29 . Ketoconazole pretreatment significantly increased TKI sensitivity exclusively in the exocrine-like PDAC cells, rendering their drug response comparable to that in the other subtypes ( Fig. 2c and Supplementary  Fig. 2g ). These results suggest that CYPs contribute to drug resistance in PDACs of the exocrine-like subtype.
CYP3A5 is expressed and inducible in exocrine-like PDAC cells
Members of the CYP3A subfamily are major contributors to xenobiotic biotransformation of small-molecule drugs in the liver 12 . npg
We thus tested expression of all three CYP3A family members-CYP3A4, CYP3A5 and CYP3A7-in PACO cell lines and DTs. qRT-PCR analysis revealed that CYP3A5 is exclusively expressed in the exocrine-like subtype at comparable or even higher levels than in normal liver and pancreas (Fig. 2d,e) . In contrast, expression of CYP3A4 and CYP3A7 was low or absent ( Supplementary Fig. 2h-k) .
The specific expression of CYP3A5 in exocrine-like PDAC cells was also confirmed at the protein level in PACO lines ( Fig. 2f  and Supplementary Fig. 2l ) and in specimens of individuals with HNF1A + tumors (Fig. 2g) . The marker-defined exocrine-like Right, growth curves of tumors using cells from one xenograft per group that were re-injected into previously untreated mice, which were then treated as described for Figure 4b npg xenografts of the validation cohort of primary PDAC xenografts also expressed significantly more CYP3A5 than those of the other two subtypes (exocrine-like versus QM-PDA: P = 0.0043; exocrine-like versus classical: P = 0.0435) (Supplementary Fig. 2m ). Consistent with these findings, expression of CYP3A5 correlated positively with that of HNF1A and inversely with expression of KRT81 in the PAAD data set (Supplementary Fig. 2n ).
Enzymes involved in xenobiotic biotransformation can be induced in response to their substrates 30 . To test whether this regulatory mechanism is also functional in PDAC cells, we measured CYP3A5 mRNA and CYP3A5 protein expression in PACO lines at steady state and in response to treatment with 10 µM dasatinib or erlotinib. Exposure to either drug boosted CYP3A5 expression in the exocrine-like, but not in the classical and QM-PDA, PACO lines (Fig. 2h) . No increase in expression of CYP3A4 or CYP3A7 was observed ( Supplementary  Fig. 2o ). Taken together, these data reveal that CYP3A5 is highly expressed, and that its expression can be further induced, in cells of the exocrine-like PDAC subtype in vitro.
CYP3A5 mediates drug resistance in exocrine-like PDAC cells
To test whether CYP3A5 metabolizes erlotinib and dasatinib in exocrine-like PDAC cells, we measured the chemical modification of these drugs in two different exocrine-like PACO lines that were transfected with either a CYP3A5-specific (siCYP3A5) or a nontargeting (siNT-control) short interfering RNA (siRNA). Quantitative mass spectrometric analysis (using liquid chromatographycoupled tandem mass spectrometry (LC-MS/MS)) 27,28 revealed a rapid conversion of erlotinib and dasatinib in siNT-controltransfected cells, as illustrated by loss of their unmodified forms from the supernatant; this did not occur in cells transfected with the siCYP3A5 (Fig. 3a and Supplementary Fig. 3a,b) . Chemical modifications by CYP enzymes can have a neutral effect, or they can activate or inactivate small-molecule inhibitors 31 . If CYP3A5 inactivates these compounds, its expression would explain the observed resistance to erlotinib and dasatinib in exocrine-like PDAC cells. Indeed, siRNA-mediated knockdown of CYP3A5 significantly and exclusively sensitized the exocrine-like PACO cells to these drugs ( Fig. 3b and Supplementary Fig. 3c,d) . As microtubule-targeting taxanes are also substrates for CYP3A family members 32, 33 , we next asked whether CYP3A5 expression affects the recently introduced paclitaxel-based treatment for PDAC 5, 6 . Treatment of PACO lines with paclitaxel indeed revealed that the exocrine-like PDAC subtype was significantly more resistant than the other two subtypes ( Fig. 3c  and Supplementary Fig. 3e-g) . To verify the role of CYP3A5 in this context, we established exocrine-like PACO lines that stably expressed control (shScr) or CYP3A5-specific (shCYP3A5) shRNAs (Fig. 3d) . Similarly to that of erlotinib and dasatinib (Supplementary Fig. 3h,i) , knockdown of CYP3A5 sensitized the exocrine-like PACO cells to paclitaxel (Fig. 3e) .
The strong upregulation of CYP3A5 in response to erlotinib, dasatinib and paclitaxel ( Fig. 2h and Supplementary Fig. 3j ) suggests a major contribution of CYP3A5 induction to the observed drug resistance. Of the genes that encode transcription factors known to regulate the expression of CYP3A family members [34] [35] [36] [37] , HNF4A and NR1I2 (also called PXR) are selectively expressed in exocrine-like PACO cells at levels comparable to those in normal liver (Fig. 3f,g) . Whereas HNF4A-dependent transcription is activated by its ubiquitous ligand linoleic acid 38 , NR1I2 initiates transcription in response to xenobiotics such as erlotinib, dasatinib and paclitaxel 39, 40 . We performed individual or combined siRNA knockdowns for HNF4A (using siHNF4A) and NR1I2 (using siNR1I2) to test their contribution to basal and induced expression of CYP3A5 (Supplementary Fig. 3k ). Basal expression of CYP3A5 was significantly reduced by knockdown of HNF4A but not NR1I2 (Fig. 3h,i and Supplementary Fig. 3l,m) . In contrast, induction of CYP3A5 expression after treatment with erlotinib, dasatinib and paclitaxel was significantly impaired by knockdown of NR1I2 but not HNF4A (Fig. 3h,i and Supplementary Fig. 3l,m) . Combined knockdown of HNF4A and NR1I2 significantly decreased both basal and druginduced CYP3A5 expression ( Fig. 3j and Supplementary Fig. 3n,o) . Next, we tested the contribution of both factors to drug resistance. Knockdown of either HNF4A or NR1I2 rendered exocrine-like PACO cells susceptible to all of the drugs tested (Fig. 3h,i and Supplementary Fig. 3l,m) . The combined knockdown of HNF4A and NR1I2 rendered the cells even more sensitive to drug treatment than that achieved by the knockdown of HNF4A or NR1I2 alone ( Fig. 3j and Supplementary Fig. 3n ).
We next asked whether ablation of CYP3A5 expression could sensitize established tumors to small-molecule drugs in vivo. We thus established subcutaneous tumors from shScr-or shCYP3A5expressing exocrine-like PACO cells in NSG mice. After the tumors reached an average volume of 200 mm 3 npg erlotinib or vehicle by oral gavage for five consecutive days followed by 2 d of rest, for a total of 14 d. Whereas treatment with erlotinib had no significant effect on the growth rate of the shScr-expressing tumors, growth of the shCYP3A5-expressing tumors was significantly inhibited ( Fig. 4a and Supplementary Fig. 4a) . Additionally, CYP3A5 expression was significantly (PACO10: P < 0.05; PACO14: P < 0.01) increased in shScr-expressing tumors after treatment of mice with erlotinib but not vehicle (Supplementary Fig. 4b) . Knockdown of CYP3A5 also significantly enhanced the response to paclitaxel treatment ( Fig. 4b  and Supplementary Fig. 4c) . To extend the in vivo treatment period, we re-injected cells recovered after treatment round one into secondary mice (round two). Even in round two, paclitaxel treatment significantly suppressed the growth of shCYP3A5-expressing tumors ( Fig. 4b and Supplementary Fig. 4c) , and CYP3A5 expression was significantly (P < 0.01) higher in shScr-expressing tumors from paclitaxel-treated mice as compared to those from vehicle-treated mice (Supplementary Fig. 4d ). We conclude that long-term suppression of CYP3A5 expression in exocrine-like xenografts does not lead to induction of alternative resistance pathways.
CYP3A5 contributes to acquired resistance in QM-PDA and classical PDAC cells
The development of secondary resistance limits the efficacy of drug treatment in PDAC 1 . We thus asked whether CYP3A5 also contributes to acquired resistance. To this end, tumors of the classical subtype were treated with paclitaxel for two rounds for a total of 32 d. Paclitaxel treatment significantly inhibited tumor growth of classical xenografts during the first round of treatment, whereas longerterm treatment led to a marked development of paclitaxel resistance (Fig. 5a) . CYP3A5 mRNA and CYP3A protein expression substantially increased after paclitaxel treatment (Fig. 5b,c) . Because we could not detect expression of CYP3A4 and CYP3A7 (Supplementary Fig. 5a) , these data suggest a role for CYP3A5 in acquired drug resistance.
To functionally explore this hypothesis, we generated paclitaxelresistant classical (PACO2 PR ) and QM-PDA (PACO7 PR ) PACO lines (Fig. 5d) . Consistent with the findings from the in vivo drug-treatment experiments, we found that CYP3A5 expression was significantly increased in the paclitaxel-resistant PACO sublines as compared to that in the control parental lines (Fig. 5e) , whereas CYP3A4 and CYP3A7 expression was undetectable (Supplementary Fig. 5b) . Similar results were obtained for dasatinib-and erlotininb-resistant lines (Supplementary Fig. 5c,d) . Inhibition of CYP3A5 by using ketoconazole (Fig. 5f) or by CYP3A5 knockdown (Fig. 5g,h) restored drug sensitivity in the paclitaxel-resistant sublines to levels comparable to that of the parental lines. Furthermore, ectopic expression of CYP3A5 in non-exocrine-like cells conferred drug resistance (Fig. 5i,j and Supplementary Fig. 5e,f) , confirming that CYP3A5 upregulation is a primary mechanism responsible for the observed acquired resistance.
CYP3A5 contributes to drug resistance in other malignancies
Expression of CYP family members has been described in a range of tumors 14, 41 . To address whether CYP3A5 mediates resistance in tumor types other than PDAC, we stained a tissue microarray (TMA) comprising 438 individual tissue samples from 33 distinct tumor types for CYP3A5 ( Fig. 6a and Supplementary Fig. 6a ). Samples from 10 of 33 tumor types expressed detectable amounts of CYP3A5. We found particularly high expression of CYP3A5 in the majority of hepatocellular carcinoma, gastric carcinoma, cervical carcinoma, adrenal gland cortical carcinoma and biliary tract cancer tissue samples, indicating that CYP3A5 may mediate drug resistance in a considerable fraction of solid tumors ( Supplementary Table 9 ). To begin to test this hypothesis, we screened a number of gastric and hepatocellular carcinoma cell lines for CYP3A5 expression. The gastric cancer cell line SNU 5 and the hepatocellular carcinoma cell line HepG2 expressed CYP3A5 at levels comparable to those in normal liver and were selected for further experiments ( Fig. 6b and Supplementary  Fig. 6b ). We found that paclitaxel exposure resulted in the induction of CYP3A5 expression in these cell lines (Supplementary Fig. 6c ) and that pretreatment with ketoconazole sensitized both cell lines to paclitaxel treatment (Fig. 6d) . We observed a similar sensitization after CYP3A5 knockdown in HepG2 cells (Fig. 6c,e and Supplementary  Fig. 6d ), suggesting that CYP3A5 expression contributes to drug resistance in tumor types other than PDAC.
DISCUSSION
Here we confirm the existence of three reported PDAC subtypes 11 and identify two surrogate markers, HNF1A and KRT81, for tumor stratification by using immunohistochemistry. Our finding-that individuals with resectable HNF1A + exocrine-like PDAC have the best survival rates-might be perceived contradictory at first. However, patient survival is not only determined by drug response; growth rate of the primary tumor as well as the propensity for, and the pattern of, metastasis also influence survival 38 . In fact, exocrine-like PACO cells are slower to expand in culture and have a delayed onset in xenograft formation as compared to PACO cells of the classical and QM-PDA subtypes (data not shown). This suggests that tumors originating from exocrine-like PDAC cells are the least aggressive PDAC subtype, despite their resistance to drug treatments.
Drug response in cancer patients is influenced by hepatic CYPs that mediate systemic drug metabolism, whereas only minor amounts of these enzymes are expressed in other tissues 42, 43 . Although a role for CYPs in tumor cell-autonomous drug detoxification has been postulated 34, [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] , this concept has never been functionally demonstrated. We now demonstrate that CYP3A5 contributes to both basal and acquired resistance to small-molecule drugs in PDAC. Because CYP3A5 is dispensable for normal physiology 56, 57 , its inhibition in cancers is a promising therapeutic option. It may be challenging to design a CYP3A5-specific inhibitor owing to the structural similarities between CYP3A family members, although a highly selective CYP3A4 inhibitor has been reported 58 . Expression of CYP family enzymes are frequently induced by their substrates 12, 37 . We show that basal and substrate-induced expression of CYP3A5 is differentially regulated by HNF4A and NR1I2. Interfering with these regulatory mechanisms may provide an alternative approach to suppress the CYP3A5 pathway, thus overcoming basal and acquired drug resistance in PDAC.
The described CYP3A5-mediated resistance mechanism is not limited to PDAC, as expression and functional analyses suggest that subsets of other cancer types may use the same resistance strategy. Consequently, CYP3A5 expression should be taken into consideration in the interpretation of results from drug trials, as targets of this enzyme probably have decreased efficacy in CYP3A5-expressing tumors.
METHODS
Methods and any associated references are available in the online version of the paper. in Supplementary Figures 1c and 2n are, in part, based upon data generated by TCGA Research Network (http://cancergenome.nih.gov/).
LC-MS/MS analysis. (S)-(−)-propranolol hydrochloride (internal standard)
was purchased from Sigma. Acetonitrile was from Bernd Kraft (Duisburg, Germany); ammonium acetate and formic acid from Merck; methanol from VWR International; and dimethylsulfoxide from Applichem. 500 µl of reaction medium was quenched with 1,000 µl of acetonitrile at each time point and mixed. After centrifugation, clear supernatants were prediluted with PACO medium and acetonitrile at a ratio of 1:25. 100 µl of the sample was transferred into a new vial, 10 µl (S)-(−)-propranolol hydrochloride solution (105 µg/liter) was added, and the solution was vigorously mixed. Calibration and quality control samples were prepared by spiking PACO medium with either dasatinib or erlotinib. 10 µl of the samples was injected onto a PerfectSil Target ODS-3 HPLC column (3 µm, 100 × 2.1 mm, MZ-Analysentechnik), using an Agilent 1100 (Agilent) binary pump and degasser, with a CTC PAL sampler (CTC Analytics). Tissue microarray. The tissue microarray (TMA) was constructed from individuals that received partial pancreatoduodenectomy for PDAC between 1991 and 2006 at the Charité University Hospital Berlin. The use of this tumor cohort for biomarker analysis has been approved by the Charité University ethics committee (EA1/06/2004). Formalin-fixed and paraffin-embedded tissue samples were used to generate tissue microarrays as previously described 66 . Briefly, each PDAC sample included was represented by three different tissue cores, each measuring 1 mm in diameter and chosen by a board of certified pathologists as being representative for the respective tumor. From the defined regions, tissue cylinders of 1.5-mm diameter were punched from each donor sample and arrayed into a new 'recipient' paraffin block using a semiautomated tissue microarrayer (Beecher Instruments). The human various cancers high-density TMA, which is composed of VA2-SBC, VB2-SBC and VC2-SBC (n = 438), was purchased from Super Bio Chips (BioCat).
Immunohistochemistry and marker-based stratification. For a list of all marker candidates tested and a summary of the results obtained see Supplementary  Table 4 . Tumor specimens were fixed in 10% formalin overnight and embedded in paraffin. For immunohistochemistry, slides were deparaffinized and rehydrated. Antigen retrieval was enhanced by boiling in a steam pot at pH 6 in Dako target retrieval solution (Dako) for 15 min, followed by cooling for 30 min and washing in distilled water. Nonspecific binding was blocked by using the Linaris Avidin/Biotin blocking Kit (Vector Labs) according to the manufacturer's instructions. Slides were incubated with primary antibodies for 30 min, rinsed in PBS-T (PBS with 0.5% Tween-20), incubated for 20 min with the appropriate secondary antibody using the Dako REAL Detection System and rinsed in PBS-T. After blocking of endogenous peroxidase and incubation with streptavidin-horseradish peroxidase (HRP) (20 min at room temperature (RT)), slides were developed with AEC (Dako) and counterstained with hematoxylin. Primary antibodies and dilutions are described in Supplementary Table 11 . All antibodies were diluted in Dako antibody diluent.
Three pathologists evaluated all of the sections independently; discordant cases were discussed using a multiheaded microscope until consensus was achieved. The study was carried out blinded as to the identity of the specimens. A case was considered positive for a given marker (CYP3A5, KRT81 and HNF1A) if the tumor cells in the respective tissue-microarray spots showed a detectable staining regardless of the strength of the signal or the number of positive cells. However, in those instances in which staining of tumor cells was detectable for any of the markers, the respective staining was usually strong. Hence, if any tumor cell was found positive for KRT81 or HNF1A expression in any of the cores, the tumor was defined as QM-PDA or exocrine-like, respectively. Stromal cells were negative in all instances; normal acinar pancreatic cells (when present) expressed HNF1A homogenously to a moderate degree but were consistently negative for the other two markers.
As whole-tissue slides were used in the validation cohort of xenografts, the scoring system was adapted to account for a higher level of heterogeneity, as observed in the samples stained for KRT81 and HNF1A. Specifically, a cutoff of at least 10% KRT81-positive tumor cells was introduced to consider a sample to be QM-PDA. Positive staining of a single tumor cell did not justify an allocation to a specific biological subtype. Additionally, the evaluation of HNF1A staining was adapted by only considering samples with moderate or strong nuclear staining reactions to be exocrine-like. A few cases with an extremely light nuclear staining reaction of HNF1A were observed, and these were not considered to represent biologically relevant HNF1A expression.
